KALA BIO, Inc. - Common Stock (KALA)
0.7822
-0.0409 (-4.97%)
NASDAQ · Last Trade: Oct 23rd, 5:28 PM EDT
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · October 20, 2025
Via Benzinga · October 20, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · October 20, 2025

KALA stock results show that Kala Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · October 20, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · October 20, 2025
Via Benzinga · October 20, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · October 1, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 30, 2025
Unusual volume stocks in Tuesday's session
Via Chartmill · September 30, 2025
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.
Via Benzinga · September 29, 2025
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
Via Benzinga · September 29, 2025
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
Via Benzinga · September 29, 2025
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
Via Benzinga · September 29, 2025
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.
Via Stocktwits · September 29, 2025
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
Via Benzinga · August 21, 2025
Via Benzinga · July 11, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 22, 2025

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.
Via Stocktwits · February 12, 2025

This morning's hotter-than-expected CPI data sent the market reeling, after the annual inflation rate rose to 3% and the 12-month core inflation rate rose to 3.3%.
Via Talk Markets · February 12, 2025

KALA stock results show that Kala Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024

KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 2, 2024

Via Benzinga · December 5, 2023